Barclays analyst Balaji Prasad maintained a Buy rating on Coherus Biosciences (CHRS – Research Report) today and set a price target of $7.00. The company’s shares closed last Friday at $2.34.
Prasad covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Idexx Laboratories, and Dr Reddy’s Laboratories. According to TipRanks, Prasad has an average return of 2.2% and a 45.93% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coherus Biosciences with a $10.71 average price target, representing a 357.69% upside. In a report released on January 23, Truist Financial also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
Based on Coherus Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $74.57 million and a GAAP net loss of $39.64 million. In comparison, last year the company earned a revenue of $45.42 million and had a GAAP net loss of $86.65 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Coherus Biosciences (CHRS) Company Description:
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Read More on CHRS:
- Biotech Alert: Searches spiking for these stocks today
- Coherus Biosciences price target lowered to $8 from $12 at Truist
- Coherus Biosciences price target lowered to $9 from $11 at Baird
- Coherus Biosciences Announces New Purchase Agreement Details
- Coherus BioSciences Sells CIMERLI® Franchise to Sandoz
